Short-Course Radiotherapy

How it works

Benefits

Dosage & preparation

Preparation

Comparisons

Highlighted claims

• The protocol selects 25 Gy in five fractions as the short-course radiotherapy schedule. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
• Short-course radiotherapy is delivered to the tumour bed and regional lymphatic drainage using IMRT or VMAT. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
• Radiotherapy may potentiate antitumour immunity through immunogenic cell death, damage-associated molecular patterns, MHC class I expression, and cGAS-STING activation. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
• Adjuvant radiotherapy has retrospective evidence for improved local control in head-and-neck mucosal melanoma. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
• Short-course hypofractionated radiotherapy may have immunological advantages over conventional fractionation. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
• Hypofractionated radiotherapy is considered potentially more effective than prolonged conventional fractionation for melanoma. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial